Author | Robert J. Motzer, MD


Optimizing Treatment Approaches in Advanced Renal Cancer

December 15, 2017

This article provides a practical perspective on the management of advanced RCC, as well as insight into the current models of risk stratification and ongoing clinical trials. The discussion will focus on the currently available systemic therapies; other strategies that are beyond the scope of this article include active surveillance and metastasectomy.

ASCO 2010: Selected Sessions in Renal Cell Carcinoma

June 21, 2010

Newly developed targeted agents in the management of advanced renal cell carcinoma have given us treatment options in this disease not imagined a decade ago.

Targeted Therapies: A Paradigm Shift in RCC

June 08, 2010

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

Poor Risk Renal Cell Carcinoma Patients: Role of New Agents

August 01, 2007

Prognostic factor models can provide important information to help patients and clinicians make treatment decisions. These decisions have become more complex in the selection of treatment for patients with metastatic renal cell carcinoma (RCC).